Following referral of TAC’s Competition Commission complaint to the Competition Tribunal, Boehringer Ingelheim and GlaxoSmithKline grant licenses for generic manufacture and sale of the ARV medicines Lamivudine and Zidovudine in South Africa and also allowing supply to other sub-Saharan countries.